Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOTION-4 antithrombotic strategies after TAVI
2020-003361-19Phase 4Active
- Sponsor
- Rigshospitalet
- Start
- Aug 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of aspirin, clopidogrel, apixaban, edoxaban, dabigatran and 2 more in cardiac morbidity (3 arms), sponsored by Rigshospitalet. Primary endpoint: Incidence of HALT at 1 year. Started Aug 2020; status: active.
02
Drugs
aspirinclopidogrelapixabanedoxabandabigatran
03
Conditions
cardiac morbidity
Beyond the preview
Go deeper on 2020-003361-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003361-19.